Key facts
- This page summarizes Elena Prokupets's Form 4 filing for C4 Therapeutics, Inc. (CCCC).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 29 Sep 2021, 18:33.
Elena Prokupets - 27 Sep 2021 Form 4 Insider Report for C4 Therapeutics, Inc. (CCCC)
- Reporting relationship
- Director
- Issuer ticker
- CCCC
- Reported as of
- 27 Sep 2021
- Net transaction value
- -$92,573
- SEC form
- 4
- Accepted by SEC
- 29 Sep 2021, 18:33:43 UTC
- Prior SEC filing
- 24 Sep 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/ Shoaib Ghias, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Elena Prokupets filed Form 4 for C4 Therapeutics, Inc. (CCCC) on 29 Sep 2021.
Change
- Previous filing in this sequence was filed on 24 Sep 2021.
- Current net transaction value: -$92,573.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CCCC
transaction
Common Stock
Sale
- Transaction value
- $26,969
- Shares
- -539
- Change %
- -1.7%
- Price
- $50.04*
- Shares after
- 31,681
- Date
- 27 Sep 2021
- Ownership
- By Spouse
- Footnotes
- F1, F2
CCCC
transaction
Common Stock
Sale
- Transaction value
- $65,604
- Shares
- -1,311
- Change %
- -0.26%
- Price
- $50.04*
- Shares after
- 503,126
- Date
- 27 Sep 2021
- Ownership
- By ERP Business Holdings, LP
- Footnotes
- F3, F4, F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 5 footnotes
Footnote F1
This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 12, 2021.
Footnote F2
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $50.00 to $50.09. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
Footnote F3
This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 15, 2021.
Footnote F4
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $50.00 to $50.19. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
Footnote F5
Shares held by ERP Business Holdings, L.P. The Reporting Person disclaims beneficial ownership of these shares except to the extent of her pecuniary interest therein.